0.65Open0.65Pre Close0 Volume69 Open Interest10.00Strike Price0.00Turnover112.09%IV17.40%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier23DDays to Expiry0.65Extrinsic Value100Contract SizeAmericanOptions Type-0.2788Delta0.1041Gamma17.42Leverage Ratio-0.0227Theta-0.0023Rho-4.85Eff Leverage0.0097Vega
Stoke Therapeutics Stock Discussion
Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome
In the rapidly evolving world of biotechnology, companies like Stoke Therapeutics are pioneering groundbreaking treatments that could potentially change the lives of patients with severe diseases. The recent buzz surrounding Stoke Therapeutics, particularly their work on an anti-epilepsy drug, STK-001, underscores the transformative potential of RNA-based therapies in addres...
No comment yet